Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey
Background Hepatitis C virus (HCV) infection is a significant health problem. The aim of this study is to evaluate the cost-effectiveness of HCV treatment and estimate its economic burden in Turkey. Methods An Excel-based disease progression model was used to estimate the HCV-infected population for...
Gespeichert in:
| Veröffentlicht in: | Hepatology international 2017-11, Vol.11 (6), p.509-516 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 516 |
|---|---|
| container_issue | 6 |
| container_start_page | 509 |
| container_title | Hepatology international |
| container_volume | 11 |
| creator | Örmeci, Necati Malhan, Simten Balık, İsmail Ergör, Gül Razavi, Homie Robbins, Sarah |
| description | Background
Hepatitis C virus (HCV) infection is a significant health problem. The aim of this study is to evaluate the cost-effectiveness of HCV treatment and estimate its economic burden in Turkey.
Methods
An Excel-based disease progression model was used to estimate the HCV-infected population for 2015–2030. Direct costs in US dollars (USD) including diagnostic, laboratory, and healthcare costs were provided by experts in the country. Indirect costs were estimated as lost productivity using the World Health Organization (WHO) disability-adjusted life years (DALYs) metric from the Global Burden of Disease study. Three scenarios were developed to estimate the cost-effectiveness of HCV treatment through 2030: Base 2016, Increase Treatment and SVR (where SVR is sustained virological response), and WHO Targets. Additionally, the WHO Targets scenario was assessed at three different treatment price points: 10,900 USD, 16,730 USD (base cost), and 27,285 USD.
Results
Cumulative total direct and indirect costs (2015–2030) for the WHO Targets scenario were estimated to be 10.8 billion USD, or a 1.5 % increase compared with Base 2016. However, by the following decade, due to a marked decline in DALYs, cumulative direct and indirect costs were estimated to be 45 % less when compared with Base 2016. At a threshold of 9125 USD, all scenarios were cost-effective.
Conclusions
By implementing the WHO Targets scenario, Turkey would be able to lower HCV prevalence by 80 % and reduce the total number of liver-related deaths by >65 % by 2030. Treating HCV infection in the country is cost-effective if healthcare and indirect costs are taken into consideration. |
| doi_str_mv | 10.1007/s12072-017-9820-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1951570394</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1968941101</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-889d911f024c4ad114350451563fc48cdaab38a3140e29df2d707062de546cbf3</originalsourceid><addsrcrecordid>eNp1kU1rVTEQhoNYbG39AW4k4MbNsTNJzkeWcqkfUHBhuw65yZze1HuSa5Kz6L835dYigqsZmOd9Z5iXsbcIHxFgvCwoYBQd4NjpSUAnX7Az1HLooFf48rmX8pS9LuUeoO8HHF6xU6FBjAj6jO1-OIo2h1R4TXyx0d4RrzviOzrYGmoofMN9KGQL8e2aPUVuo-e2lOSCreQ5uRTTEhwPy8G6ytPMayZbF4qVh8hv1vyTHi7YyWz3hd481XN2-_nqZvO1u_7-5dvm03Xn5ChqN03aa8QZhHLKekQle1A99oOcnZqct3YrJytRAQntZ-FHGGEQnno1uO0sz9mHo-8hp18rlWqWUBzt9zZSWotB3cxGkFo19P0_6H1ac2zXNWqYtEIEbBQeKZdTKZlmc8hhsfnBIJjHGMwxBtNiMI8xGNk0756c1-1C_lnx5-8NEEegtFG8o_zX6v-6_gaKApHT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1968941101</pqid></control><display><type>article</type><title>Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey</title><source>SpringerLink Journals</source><creator>Örmeci, Necati ; Malhan, Simten ; Balık, İsmail ; Ergör, Gül ; Razavi, Homie ; Robbins, Sarah</creator><creatorcontrib>Örmeci, Necati ; Malhan, Simten ; Balık, İsmail ; Ergör, Gül ; Razavi, Homie ; Robbins, Sarah</creatorcontrib><description>Background
Hepatitis C virus (HCV) infection is a significant health problem. The aim of this study is to evaluate the cost-effectiveness of HCV treatment and estimate its economic burden in Turkey.
Methods
An Excel-based disease progression model was used to estimate the HCV-infected population for 2015–2030. Direct costs in US dollars (USD) including diagnostic, laboratory, and healthcare costs were provided by experts in the country. Indirect costs were estimated as lost productivity using the World Health Organization (WHO) disability-adjusted life years (DALYs) metric from the Global Burden of Disease study. Three scenarios were developed to estimate the cost-effectiveness of HCV treatment through 2030: Base 2016, Increase Treatment and SVR (where SVR is sustained virological response), and WHO Targets. Additionally, the WHO Targets scenario was assessed at three different treatment price points: 10,900 USD, 16,730 USD (base cost), and 27,285 USD.
Results
Cumulative total direct and indirect costs (2015–2030) for the WHO Targets scenario were estimated to be 10.8 billion USD, or a 1.5 % increase compared with Base 2016. However, by the following decade, due to a marked decline in DALYs, cumulative direct and indirect costs were estimated to be 45 % less when compared with Base 2016. At a threshold of 9125 USD, all scenarios were cost-effective.
Conclusions
By implementing the WHO Targets scenario, Turkey would be able to lower HCV prevalence by 80 % and reduce the total number of liver-related deaths by >65 % by 2030. Treating HCV infection in the country is cost-effective if healthcare and indirect costs are taken into consideration.</description><identifier>ISSN: 1936-0533</identifier><identifier>EISSN: 1936-0541</identifier><identifier>DOI: 10.1007/s12072-017-9820-3</identifier><identifier>PMID: 29027109</identifier><language>eng</language><publisher>New Delhi: Springer India</publisher><subject>Colorectal Surgery ; Cost analysis ; Costs ; Diagnostic systems ; Disease control ; Economic impact ; Economic models ; Health care ; Hepatitis ; Hepatitis C ; Hepatology ; Impact analysis ; Infections ; Liver ; Medical treatment ; Medicine ; Medicine & Public Health ; Original Article ; Surgery ; Viruses</subject><ispartof>Hepatology international, 2017-11, Vol.11 (6), p.509-516</ispartof><rights>Asian Pacific Association for the Study of the Liver 2017</rights><rights>Hepatology International is a copyright of Springer, (2017). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-889d911f024c4ad114350451563fc48cdaab38a3140e29df2d707062de546cbf3</citedby><cites>FETCH-LOGICAL-c372t-889d911f024c4ad114350451563fc48cdaab38a3140e29df2d707062de546cbf3</cites><orcidid>0000-0002-8909-2102</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12072-017-9820-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12072-017-9820-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29027109$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Örmeci, Necati</creatorcontrib><creatorcontrib>Malhan, Simten</creatorcontrib><creatorcontrib>Balık, İsmail</creatorcontrib><creatorcontrib>Ergör, Gül</creatorcontrib><creatorcontrib>Razavi, Homie</creatorcontrib><creatorcontrib>Robbins, Sarah</creatorcontrib><title>Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey</title><title>Hepatology international</title><addtitle>Hepatol Int</addtitle><addtitle>Hepatol Int</addtitle><description>Background
Hepatitis C virus (HCV) infection is a significant health problem. The aim of this study is to evaluate the cost-effectiveness of HCV treatment and estimate its economic burden in Turkey.
Methods
An Excel-based disease progression model was used to estimate the HCV-infected population for 2015–2030. Direct costs in US dollars (USD) including diagnostic, laboratory, and healthcare costs were provided by experts in the country. Indirect costs were estimated as lost productivity using the World Health Organization (WHO) disability-adjusted life years (DALYs) metric from the Global Burden of Disease study. Three scenarios were developed to estimate the cost-effectiveness of HCV treatment through 2030: Base 2016, Increase Treatment and SVR (where SVR is sustained virological response), and WHO Targets. Additionally, the WHO Targets scenario was assessed at three different treatment price points: 10,900 USD, 16,730 USD (base cost), and 27,285 USD.
Results
Cumulative total direct and indirect costs (2015–2030) for the WHO Targets scenario were estimated to be 10.8 billion USD, or a 1.5 % increase compared with Base 2016. However, by the following decade, due to a marked decline in DALYs, cumulative direct and indirect costs were estimated to be 45 % less when compared with Base 2016. At a threshold of 9125 USD, all scenarios were cost-effective.
Conclusions
By implementing the WHO Targets scenario, Turkey would be able to lower HCV prevalence by 80 % and reduce the total number of liver-related deaths by >65 % by 2030. Treating HCV infection in the country is cost-effective if healthcare and indirect costs are taken into consideration.</description><subject>Colorectal Surgery</subject><subject>Cost analysis</subject><subject>Costs</subject><subject>Diagnostic systems</subject><subject>Disease control</subject><subject>Economic impact</subject><subject>Economic models</subject><subject>Health care</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatology</subject><subject>Impact analysis</subject><subject>Infections</subject><subject>Liver</subject><subject>Medical treatment</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Original Article</subject><subject>Surgery</subject><subject>Viruses</subject><issn>1936-0533</issn><issn>1936-0541</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp1kU1rVTEQhoNYbG39AW4k4MbNsTNJzkeWcqkfUHBhuw65yZze1HuSa5Kz6L835dYigqsZmOd9Z5iXsbcIHxFgvCwoYBQd4NjpSUAnX7Az1HLooFf48rmX8pS9LuUeoO8HHF6xU6FBjAj6jO1-OIo2h1R4TXyx0d4RrzviOzrYGmoofMN9KGQL8e2aPUVuo-e2lOSCreQ5uRTTEhwPy8G6ytPMayZbF4qVh8hv1vyTHi7YyWz3hd481XN2-_nqZvO1u_7-5dvm03Xn5ChqN03aa8QZhHLKekQle1A99oOcnZqct3YrJytRAQntZ-FHGGEQnno1uO0sz9mHo-8hp18rlWqWUBzt9zZSWotB3cxGkFo19P0_6H1ac2zXNWqYtEIEbBQeKZdTKZlmc8hhsfnBIJjHGMwxBtNiMI8xGNk0756c1-1C_lnx5-8NEEegtFG8o_zX6v-6_gaKApHT</recordid><startdate>20171101</startdate><enddate>20171101</enddate><creator>Örmeci, Necati</creator><creator>Malhan, Simten</creator><creator>Balık, İsmail</creator><creator>Ergör, Gül</creator><creator>Razavi, Homie</creator><creator>Robbins, Sarah</creator><general>Springer India</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8909-2102</orcidid></search><sort><creationdate>20171101</creationdate><title>Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey</title><author>Örmeci, Necati ; Malhan, Simten ; Balık, İsmail ; Ergör, Gül ; Razavi, Homie ; Robbins, Sarah</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-889d911f024c4ad114350451563fc48cdaab38a3140e29df2d707062de546cbf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Colorectal Surgery</topic><topic>Cost analysis</topic><topic>Costs</topic><topic>Diagnostic systems</topic><topic>Disease control</topic><topic>Economic impact</topic><topic>Economic models</topic><topic>Health care</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatology</topic><topic>Impact analysis</topic><topic>Infections</topic><topic>Liver</topic><topic>Medical treatment</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Original Article</topic><topic>Surgery</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Örmeci, Necati</creatorcontrib><creatorcontrib>Malhan, Simten</creatorcontrib><creatorcontrib>Balık, İsmail</creatorcontrib><creatorcontrib>Ergör, Gül</creatorcontrib><creatorcontrib>Razavi, Homie</creatorcontrib><creatorcontrib>Robbins, Sarah</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Örmeci, Necati</au><au>Malhan, Simten</au><au>Balık, İsmail</au><au>Ergör, Gül</au><au>Razavi, Homie</au><au>Robbins, Sarah</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey</atitle><jtitle>Hepatology international</jtitle><stitle>Hepatol Int</stitle><addtitle>Hepatol Int</addtitle><date>2017-11-01</date><risdate>2017</risdate><volume>11</volume><issue>6</issue><spage>509</spage><epage>516</epage><pages>509-516</pages><issn>1936-0533</issn><eissn>1936-0541</eissn><abstract>Background
Hepatitis C virus (HCV) infection is a significant health problem. The aim of this study is to evaluate the cost-effectiveness of HCV treatment and estimate its economic burden in Turkey.
Methods
An Excel-based disease progression model was used to estimate the HCV-infected population for 2015–2030. Direct costs in US dollars (USD) including diagnostic, laboratory, and healthcare costs were provided by experts in the country. Indirect costs were estimated as lost productivity using the World Health Organization (WHO) disability-adjusted life years (DALYs) metric from the Global Burden of Disease study. Three scenarios were developed to estimate the cost-effectiveness of HCV treatment through 2030: Base 2016, Increase Treatment and SVR (where SVR is sustained virological response), and WHO Targets. Additionally, the WHO Targets scenario was assessed at three different treatment price points: 10,900 USD, 16,730 USD (base cost), and 27,285 USD.
Results
Cumulative total direct and indirect costs (2015–2030) for the WHO Targets scenario were estimated to be 10.8 billion USD, or a 1.5 % increase compared with Base 2016. However, by the following decade, due to a marked decline in DALYs, cumulative direct and indirect costs were estimated to be 45 % less when compared with Base 2016. At a threshold of 9125 USD, all scenarios were cost-effective.
Conclusions
By implementing the WHO Targets scenario, Turkey would be able to lower HCV prevalence by 80 % and reduce the total number of liver-related deaths by >65 % by 2030. Treating HCV infection in the country is cost-effective if healthcare and indirect costs are taken into consideration.</abstract><cop>New Delhi</cop><pub>Springer India</pub><pmid>29027109</pmid><doi>10.1007/s12072-017-9820-3</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-8909-2102</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1936-0533 |
| ispartof | Hepatology international, 2017-11, Vol.11 (6), p.509-516 |
| issn | 1936-0533 1936-0541 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1951570394 |
| source | SpringerLink Journals |
| subjects | Colorectal Surgery Cost analysis Costs Diagnostic systems Disease control Economic impact Economic models Health care Hepatitis Hepatitis C Hepatology Impact analysis Infections Liver Medical treatment Medicine Medicine & Public Health Original Article Surgery Viruses |
| title | Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T00%3A40%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Scenarios%20to%20manage%20the%20hepatitis%20C%20disease%20burden%20and%20associated%20economic%20impact%20of%20treatment%20in%20Turkey&rft.jtitle=Hepatology%20international&rft.au=%C3%96rmeci,%20Necati&rft.date=2017-11-01&rft.volume=11&rft.issue=6&rft.spage=509&rft.epage=516&rft.pages=509-516&rft.issn=1936-0533&rft.eissn=1936-0541&rft_id=info:doi/10.1007/s12072-017-9820-3&rft_dat=%3Cproquest_cross%3E1968941101%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1968941101&rft_id=info:pmid/29027109&rfr_iscdi=true |